Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier
- PMID: 20463931
- PMCID: PMC2865010
- DOI: 10.2147/ijn.s8905
Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier
Abstract
Despite significant advances in highly active antiretroviral therapy (HAART), the prevalence of neuroAIDS remains high. This is mainly attributed to inability of antiretroviral therapy (ART) to cross the blood-brain barrier (BBB), thus resulting in insufficient drug concentration within the brain. Therefore, development of an active drug targeting system is an attractive strategy to increase the efficacy and delivery of ART to the brain. We report herein development of magnetic azidothymidine 5'-triphosphate (AZTTP) liposomal nanoformulation and its ability to transmigrate across an in vitro BBB model by application of an external magnetic field. We hypothesize that this magnetically guided nanoformulation can transverse the BBB by direct transport or via monocyte-mediated transport. Magnetic AZTTP liposomes were prepared using a mixture of phosphatidyl choline and cholesterol. The average size of prepared liposomes was about 150 nm with maximum drug and magnetite loading efficiency of 54.5% and 45.3%, respectively. Further, magnetic AZTTP liposomes were checked for transmigration across an in vitro BBB model using direct or monocyte-mediated transport by application of an external magnetic field. The results show that apparent permeability of magnetic AZTTP liposomes was 3-fold higher than free AZTTP. Also, the magnetic AZTTP liposomes were efficiently taken up by monocytes and these magnetic monocytes showed enhanced transendothelial migration compared to normal/non-magnetic monocytes in presence of an external magnetic field. Thus, we anticipate that the developed magnetic nanoformulation can be used for targeting active nucleotide analog reverse transcriptase inhibitors to the brain by application of an external magnetic force and thereby eliminate the brain HIV reservoir and help to treat neuroAIDS.
Keywords: AZTTP; HIV-1 infectivity; blood–brain barrier; magnetic liposomes; transendothelial migration.
Figures





Similar articles
-
AZT 5'-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells.J Neurovirol. 2009 Jul;15(4):343-7. doi: 10.1080/13550280903062813. J Neurovirol. 2009. PMID: 19575326
-
Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).In Vivo. 2000 May-Jun;14(3):377-88. In Vivo. 2000. PMID: 10904870
-
Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages.J Control Release. 2006 Dec 1;116(3):346-52. doi: 10.1016/j.jconrel.2006.09.016. Epub 2006 Oct 3. J Control Release. 2006. PMID: 17113178
-
Polymeric nanogel formulations of nucleoside analogs.Expert Opin Drug Deliv. 2007 Jan;4(1):5-17. doi: 10.1517/17425247.4.1.5. Expert Opin Drug Deliv. 2007. PMID: 17184158 Free PMC article. Review.
-
Shuttle-mediated drug delivery to the brain.Angew Chem Int Ed Engl. 2011 Aug 22;50(35):7998-8014. doi: 10.1002/anie.201006565. Epub 2011 Jun 30. Angew Chem Int Ed Engl. 2011. PMID: 21721080 Review.
Cited by
-
Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers.Pharmaceutics. 2020 Feb 18;12(2):171. doi: 10.3390/pharmaceutics12020171. Pharmaceutics. 2020. PMID: 32085535 Free PMC article. Review.
-
Antiretroviral neurotoxicity.J Neurovirol. 2012 Oct;18(5):388-99. doi: 10.1007/s13365-012-0120-3. Epub 2012 Jul 19. J Neurovirol. 2012. PMID: 22811264 Free PMC article.
-
Towards nanomedicines for neuroAIDS.Rev Med Virol. 2014 Mar;24(2):103-24. doi: 10.1002/rmv.1778. Epub 2014 Jan 7. Rev Med Virol. 2014. PMID: 24395761 Free PMC article. Review.
-
Designing Novel Nanoformulations Targeting Glutamate Transporter Excitatory Amino Acid Transporter 2: Implications in Treating Drug Addiction.J Pers Nanomed. 2015;1(1):3-9. Epub 2015 Jul 27. J Pers Nanomed. 2015. PMID: 26635971 Free PMC article.
-
Effect of human immunodeficiency virus on blood-brain barrier integrity and function: an update.Front Cell Neurosci. 2015 Jun 10;9:212. doi: 10.3389/fncel.2015.00212. eCollection 2015. Front Cell Neurosci. 2015. PMID: 26113810 Free PMC article. Review.
References
-
- Pang S, Koyangi Y, Miles S, Wiley C, Harry V, Chen I. High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature. 1990;34:85–89. - PubMed
-
- Spencer DC, Price RW. Human immunodeficiency virus and the central nervous system. Annu Rev Microbiol. 1992;46:655–693. - PubMed
-
- Lipton SA, Gendelman HE. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med. 1995;332:934–940. - PubMed
-
- Lesniak MS, Brem H. Targeted therapy for brain tumors. Nat Rev Drug Discov. 2004;3(6):499–508. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources